Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. BridgeBio Pharma Inc shares valued at $171,680 were sold by Valantine Hannah on Jun 10 ’25. At $40.00 per share, Valantine Hannah sold 4,292 shares. The insider’s holdings dropped to 1,764 shares worth approximately $70560.0 following the completion of this transaction.
Also, HANNAH A VALANTINE purchased 4,292 shares, netting a total of over 171,680 in proceeds.
Before that, Kumar Neil had sold 75,000 shares from its account. In a trade valued at $2,504,978, the Chief Executive Officer traded BridgeBio Pharma Inc shares for $33.40 each. Upon closing the transaction, the insider’s holdings decreased to 75,000 shares, worth approximately $191.94 million.
As published in their initiating research note from Wolfe Research on June 17, 2025, BridgeBio Pharma Inc [BBIO] has been an Outperform and the price target has been revised to $49. Analysts at Redburn Atlantic started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of October 16, 2024, Scotiabank has initiated its “Sector outperform” rating for BBIO. Earlier on October 03, 2024, Oppenheimer initiated its rating. Their recommendation was “a Perform” for BBIO stock.
Analyzing BBIO Stock Performance
On last trading session,, BridgeBio Pharma Inc [NASDAQ: BBIO] plunged -0.17% to $40.00. The stock’s lowest price that day was $39.652, but it reached a high of $41.685 in the same session. During the last five days, there has been a surge of approximately 2.43%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 45.77%. Shares of the company reached a 52-week high of $41.71 on 06/18/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 39.20, which, if violated, would cause prices to drop to 38.39. In the upper region, resistance lies at 41.26. The next price resistance is at 42.51. RSI (Relative Strength Index) is 64.24 on the 14-day chart, showing neutral technical sentiment.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.19 million shares to 21.99 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 22.18 million shares. A decline of -0.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.62 of the overall float, the days-to-cover ratio (short ratio) decline to 6.62.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 79.69% from the previous closing price of $40.07. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On September 04, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $46.
